Generic Drugs Sales

Generic Drugs Sales Market Outlook

The global generic drugs sales market was valued at approximately USD 400 billion in 2025, with a projected compound annual growth rate (CAGR) of around 6.5% from 2025 to 2035. The significant growth in this market can be attributed to several factors including the rising prevalence of chronic diseases, increasing pressure on healthcare systems to reduce costs, and the growing acceptance of generic drugs by both healthcare providers and patients. Furthermore, the expiration of patents for numerous blockbuster drugs has paved the way for generic alternatives to enter the market. This, coupled with the increasing investments in research and development of generics, particularly in developing regions, is expected to trigger substantial growth in the sector over the forecast period. Additionally, the emphasis on affordable healthcare solutions is likely to boost the adoption of generics further.

Growth Factor of the Market

The growth factors of the generic drugs market are multifaceted, stemming from a combination of economic, demographic, and technological drivers. Firstly, the rising aging population worldwide is more susceptible to chronic health issues, which consequently propels the demand for affordable medication options. Government-led initiatives promoting the use of generics to lower healthcare costs also play a pivotal role. Furthermore, advancements in pharmaceutical technology have led to improved formulations and manufacturing processes, enhancing the safety and efficacy of generic drugs. As healthcare costs continue to rise, both consumers and healthcare providers are increasingly leaning toward generic options. The COVID-19 pandemic has further accelerated the shift towards generics, as patients and healthcare systems alike are seeking cost-effective ways to manage healthcare expenditures.

Key Highlights of the Market

• The global generic drugs market is expected to grow at a CAGR of 6.5% from 2025 to 2035.
• North America currently holds the largest market share, driven by advanced healthcare infrastructure and high generic drug adoption.
• Increasing prevalence of chronic diseases and aging population are significant drivers of market growth.
• The rise in online pharmacies is facilitating access to generic drugs, especially during the COVID-19 pandemic.
• The segment of generic biologics is anticipated to witness rapid growth due to advancements in biopharmaceutical technology.

By Product Type

Generic Prescribed Drugs:

Generic prescribed drugs are among the most significant segments of the generic drugs market, representing a substantial share due to their wide acceptance and use in managing various health conditions. These medications, which are bioequivalent to their branded counterparts, offer the same therapeutic effects at a significantly lower price point. As healthcare systems continue to advocate for cost-effective solutions, the demand for these drugs is escalating. Moreover, the expiration of patents on numerous branded drugs has led to an influx of generics entering the market, thus providing a broader range of options for healthcare providers. The ability to cater to diverse therapeutic areas, including chronic diseases, is a key driver for this segment's growth.

Over-the-Counter Generic Drugs:

Over-the-counter (OTC) generic drugs are an essential component of the generic drug market, catering to consumers who seek accessible and cost-effective treatment options for minor health issues. The growing trend of self-medication among consumers has significantly fueled the demand for OTC generics. As awareness about health and wellness increases, more individuals are opting for OTC generics for conditions such as headaches, allergies, and digestive disorders. Additionally, regulatory approvals for many OTC generics have become more streamlined, easing their entry into the market. The ability of these products to provide effective relief without the need for a prescription makes them increasingly popular among consumers, driving growth in this segment.

Generic Biologics:

Generic biologics, also known as biosimilars, represent a rapidly emerging segment within the generic drugs market. With the patent expirations of several pioneering biologic medications, the opportunity for generics in this category has expanded considerably. Generic biologics are designed to be highly similar to already approved biologic products, offering comparable safety and efficacy profiles. The rising prevalence of conditions treated with biologics, such as cancer and autoimmune diseases, is driving demand for these alternatives. Additionally, regulatory bodies are increasingly focusing on facilitating the approval of biosimilars, which is expected to bolster market growth. As stakeholders continue to prioritize cost-effective treatments, the generic biologics segment is poised for significant advancement.

Generic Vaccines:

The segment of generic vaccines is gaining traction in the global market, primarily due to the pressing need for affordable immunizations. The ongoing global health challenges, such as the COVID-19 pandemic, have underscored the importance of widespread vaccination. Generic vaccines offer a cost-effective solution to enhance immunization coverage, especially in low- and middle-income countries. The market for these vaccines is supported by public health initiatives and government policies aimed at increasing access to immunizations. Furthermore, the rise in research and development for generic formulations of established vaccines is opening new avenues for market growth. The emphasis on global health security and preventive healthcare is further solidifying the position of generic vaccines in the market.

Generic Topical Medications:

Generic topical medications encompass a range of products designed for localized treatment of various skin conditions and ailments. This segment includes creams, ointments, and gels that are often prescribed for conditions such as dermatitis, psoriasis, and infections. The growing prevalence of skin disorders, coupled with the rising demand for non-invasive treatment options, is driving the growth of generic topical medications. Healthcare providers and patients alike appreciate the affordability of generics, which enables access to necessary treatments without the financial burden associated with branded alternatives. Furthermore, the expansion of research into novel formulations and delivery mechanisms for topical treatments is expected to enhance the effectiveness of these products, further increasing their adoption.

By Application

Cardiovascular Diseases:

The application of generic drugs in the treatment of cardiovascular diseases is significant, as this group of disorders represents a leading cause of mortality globally. Generic medications are crucial in managing conditions such as hypertension, heart failure, and arrhythmias, as they offer effective treatment options at reduced costs. The increasing prevalence of risk factors associated with cardiovascular diseases, including obesity and diabetes, is driving the demand for these drugs. Additionally, the growing awareness of heart health is encouraging patients to opt for generics, which can provide comparable efficacy to branded alternatives. As healthcare systems continue to emphasize preventive care, the role of generic drugs in this arena will likely expand, ensuring better accessibility for patients.

Central Nervous System Disorders:

The segment focusing on central nervous system (CNS) disorders, which includes conditions such as depression, anxiety, and epilepsy, has witnessed substantial growth in the generic drugs market. The rising incidence of CNS disorders globally is prompting the need for effective and affordable treatment options. Generic drugs have become integral in the management of these conditions, providing patients with access to necessary medications without the often prohibitive costs associated with branded drugs. Furthermore, the growing acknowledgment of mental health issues and the importance of early intervention is fueling the demand for generics in this segment. Research into new formulations of established CNS medications is also paving the way for advancements in treatment options.

Oncology:

The oncology segment of the generic drugs market is experiencing notable growth, driven by the increasing incidence of cancer worldwide. The high cost of cancer treatment has led to a significant push toward generic alternatives that can provide effective therapies at lower prices. Generic oncology drugs are critical in enhancing patient access to necessary treatments, particularly in regions where healthcare budgets are constrained. As awareness about the benefits of generic medications continues to rise, healthcare providers are increasingly prescribing generics for various cancer types. Additionally, ongoing research and clinical trials aimed at improving the efficacy of generic oncology drugs are expected to further enhance market growth in this segment.

Diabetes:

Diabetes is a chronic health condition that requires continuous management, making the availability of affordable medications essential. The application of generic drugs in diabetes care, including insulin and oral hypoglycemic agents, is crucial for enabling patients to maintain their health without financial strain. The rising prevalence of diabetes globally, driven by lifestyle changes and increasing obesity rates, underscores the importance of generic options. They not only offer cost savings but also ensure that patients can adhere to their treatment regimens. As healthcare systems increasingly focus on preventing complications associated with diabetes, the demand for generic drugs in this application is expected to continue to grow.

Respiratory Diseases:

The rising incidence of respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), has created a significant demand for effective treatment solutions. Generic drugs play a crucial role in managing these conditions, as they provide affordable alternatives to brand-name inhalers and other medications. The increasing awareness about respiratory health issues, coupled with the rising prevalence of air pollution and smoking, has further enhanced the need for effective medications. Generic respiratory medications are not only cost-effective but also essential in ensuring that individuals can access the necessary treatments to manage their conditions. As research continues to develop more effective formulations, the generic drugs market in this segment is poised for sustained growth.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies are a critical distribution channel for generic drugs, providing essential medications to patients admitted for various medical conditions. These pharmacies have the advantage of direct access to healthcare providers, facilitating the prompt dispensing of medications. The increasing focus on hospital-based care and the implementation of formulary management practices is driving the adoption of generics within hospitals. Furthermore, hospitals are increasingly aware of the cost benefits associated with generic drugs, leading to a higher preference for these options in their drug procurement processes. The emphasis on patient safety and the need for effective treatments are key factors contributing to the growth of this distribution channel.

Retail Pharmacies:

Retail pharmacies serve as a primary source for consumers seeking prescription and over-the-counter medications, including generics. This distribution channel is experiencing robust growth due to the convenience and accessibility it offers patients. The increasing awareness of generic drug benefits among consumers is driving demand, as patients often seek affordable alternatives to branded medications. Moreover, retail pharmacies frequently promote generic options through marketing campaigns and pricing strategies, further encouraging uptake. As healthcare continues to shift towards patient-centered care, retail pharmacies are poised to play a pivotal role in delivering generic medications to communities.

Online Pharmacies:

The rise of online pharmacies is transforming the distribution landscape for generic drugs, providing consumers with unprecedented access to medications. The convenience of ordering medications from the comfort of home, coupled with competitive pricing, is driving the growth of this channel. Online pharmacies often offer a wide selection of generics, making it easier for patients to find necessary treatments. The COVID-19 pandemic has further accelerated the trend toward online pharmaceutical services, as consumers seek safe alternatives to traditional brick-and-mortar stores. As regulatory frameworks evolve to accommodate the growing online pharmacy sector, this distribution channel is expected to continue expanding.

Drug Stores:

Drug stores have long been a staple distribution channel for pharmaceuticals, including generic drugs. As consumer preferences shift toward convenience, drug stores are adapting by expanding their offerings of generic medications. The relatively low price points of generics are enticing to cost-conscious consumers, and many drug stores are actively promoting their generic lines as part of their marketing strategies. Additionally, the integration of health services into drug stores is encouraging greater consumer engagement and loyalty. As drug stores continue to evolve and adapt to changing market dynamics, their role in the generic drugs market will remain significant.

Clinics:

Clinics are an important distribution channel for generic drugs, particularly for patients seeking primary care. Many clinics prioritize cost-effective treatment options, often prescribing generic medications to ensure affordability for their patients. The close relationship between healthcare providers and patients in clinic settings facilitates the effective communication of the benefits of generics. Furthermore, as clinics increasingly focus on population health management and preventive care, the demand for affordable medications will continue to rise. The strong emphasis on patient education regarding treatment options is likely to bolster the growth of generics in clinic settings.

By Ingredient Type

Active Pharmaceutical Ingredients:

Active pharmaceutical ingredients (APIs) are crucial components of generic drug formulations, serving as the primary substances responsible for the therapeutic effect. The market for generic drugs is significantly influenced by the growing need for quality APIs, as they directly impact the effectiveness and safety of medications. The increasing globalization of the pharmaceutical supply chain has led to more competitive API pricing, which benefits generic drug manufacturers. The continuous investment in the development and production of high-quality APIs is expected to drive growth in this segment. Additionally, the rising trend of outsourcing API production to specialized manufacturers is enhancing the supply chain efficiency for generic drugs.

Inactive Ingredients:

Inactive ingredients play a vital role in the formulation of generic drugs, serving as excipients that enhance the drug's stability, bioavailability, and overall effectiveness. The demand for generics is closely linked to the evolving knowledge of formulation science, particularly in optimizing inactive ingredients for improved drug delivery. As regulatory bodies enforce stringent guidelines regarding the quality of excipients, manufacturers are increasingly focused on sourcing high-quality inactive ingredients to ensure compliance. The growing trend of personalized medicine is also influencing the selection of inactive ingredients, leading to innovations in formulations that cater to specific patient needs. As the emphasis on drug quality and efficacy continues to rise, the importance of inactive ingredients in the generic drugs market will remain significant.

By Region

The North American region currently dominates the global generic drugs market, accounting for approximately 45% of the overall market share. The region’s advanced healthcare infrastructure, coupled with a high rate of generic drug utilization among healthcare providers and patients, contributes significantly to its leading position. Furthermore, the American healthcare system's emphasis on cost-saving measures, especially in light of rising healthcare expenditures, has encouraged the adoption of generics. The market in North America is projected to grow at a CAGR of about 6.2% from 2025 to 2035, driven by ongoing patent expirations of high-value drugs and the continued push for affordable healthcare solutions.

In Europe, the generic drugs market is also witnessing robust growth, holding approximately 30% of the global share. The European Union has implemented various regulatory measures to promote the use of generics, resulting in increased market penetration across member states. Countries such as Germany, the UK, and France are at the forefront of this growth, as they have well-established frameworks for generic drug approval and promotion. Additionally, the rising healthcare costs within the region, alongside an aging population, are significant factors fueling demand for affordable medication options. The European market is expected to grow at a CAGR of 6.0% during the same forecast period, underscoring the region's commitment to enhancing patient access to generic drugs.

Opportunities

The generic drugs market is poised for significant opportunities in the coming years, particularly with the increasing emphasis on patient-centered care and cost-effective treatment solutions. As healthcare systems around the world continue to grapple with rising costs, there is a strong push toward utilizing generic medications as a means to alleviate financial burdens on patients and payers alike. The ongoing trend toward value-based care is encouraging healthcare providers to consider generics as they seek to optimize patient outcomes while managing costs. Moreover, the growing awareness of the safety and efficacy of generics is expected to facilitate greater acceptance among both healthcare professionals and patients, creating a favorable environment for market expansion.

Additionally, the expansion of digital health technologies presents new opportunities for the generic drugs market. The increasing use of telemedicine and mobile health applications is reshaping how patients access healthcare, including the procurement of medications. Online pharmacies are gaining traction as consumers seek convenient alternatives for obtaining generic drugs. This shift is particularly relevant in the post-COVID-19 landscape, where individuals prioritize safety and convenience. As digital health solutions continue to evolve, they are expected to play a pivotal role in enhancing access to generic medications, thereby driving growth in the market.

Threats

Despite the promising growth prospects for the generic drugs market, several threats pose challenges to its development. One significant concern is the increasing competition from branded drug manufacturers who are investing heavily in marketing strategies to promote their products, often casting doubt on the efficacy of generics. Additionally, the complexity of the regulatory landscape presents hurdles for generic drug manufacturers, particularly regarding the approval processes for new generics and biosimilars. This complexity can result in delays and increased costs, which may discourage new entrants into the market. Furthermore, the risk of market consolidation among major pharmaceutical players can lead to reduced competition and higher prices, ultimately hindering the growth of the generic drugs sector.

Another critical threat is the potential for supply chain disruptions, which can impact the availability of generic medications. Factors such as geopolitical tensions, natural disasters, or pandemics can create vulnerabilities in the supply chain, leading to shortages of essential generic drugs. The reliance on a limited number of suppliers for key active pharmaceutical ingredients further exacerbates this issue. To mitigate these threats, stakeholders across the industry must focus on enhancing supply chain resilience and exploring diversified sourcing strategies to ensure a steady supply of generics in the market.

Competitor Outlook

• Teva Pharmaceutical Industries Ltd.
• Mylan N.V. (now part of Viatris)
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories
• Amgen Inc.
• Roche Holding AG
• Pfizer Inc.
• Sandoz International GmbH
• Novartis AG
• Hikma Pharmaceuticals Plc
• Apotex Inc.
• Alvogen
• Zydus Cadila
• Lupin Pharmaceuticals
• Glenmark Pharmaceuticals Ltd.

The competitive landscape of the generic drugs market is characterized by a diverse array of players, ranging from established multinational corporations to emerging biotech firms. Major players such as Teva Pharmaceutical Industries Ltd. and Mylan N.V. dominate the market, leveraging extensive portfolios of generic medications and significant research and development capabilities. These companies have positioned themselves as leaders by investing in advanced manufacturing technologies and forming strategic alliances to enhance their market presence. The competitive strategy of these firms often revolves around maintaining high-quality standards for their products while optimizing operational efficiencies to reduce costs.

Additionally, the rise of biosimilars has opened new avenues for competition, with companies like Amgen and Roche investing in the development and commercialization of generic biologics. This segment is gaining traction as healthcare providers seek cost-effective alternatives to high-priced biologic therapies. The competition in the biosimilars market is fierce, with brands focusing on differentiating their products through clinical efficacy, safety profiles, and patient access initiatives. As regulatory environments continue to evolve, firms that successfully navigate these changes while maintaining product quality will emerge as key players in the generic drugs market.

Emerging firms such as Alvogen and Glenmark Pharmaceuticals Ltd. are capitalizing on niche markets and specialized generics, leveraging agility and innovation to compete with larger corporations. These companies often focus on underserved therapeutic areas or develop unique formulation technologies that differentiate their products. Additionally, the growing trend of outsourcing manufacturing to specialized contract manufacturers is allowing these companies to scale operations without the heavy capital investment associated with establishing production facilities. As the market for generics continues to evolve, these emerging players are expected to play a significant role in driving innovation and competition in the sector.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Alvogen
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Apotex Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Zydus Cadila
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Lupin Pharmaceuticals
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Hikma Pharmaceuticals Plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Sandoz International GmbH
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Glenmark Pharmaceuticals Ltd.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Mylan N.V. (now part of Viatris)
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Sun Pharmaceutical Industries Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Dr. Reddy’s Laboratories
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Generic Drugs Sales Market, By Application
    • 6.1.1 Cardiovascular Diseases
    • 6.1.2 Central Nervous System Disorders
    • 6.1.3 Oncology
    • 6.1.4 Diabetes
    • 6.1.5 Respiratory Diseases
  • 6.2 Generic Drugs Sales Market, By Product Type
    • 6.2.1 Generic Prescribed Drugs
    • 6.2.2 Over-the-Counter Generic Drugs
    • 6.2.3 Generic Biologics
    • 6.2.4 Generic Vaccines
    • 6.2.5 Generic Topical Medications
  • 6.3 Generic Drugs Sales Market, By Ingredient Type
    • 6.3.1 Active Pharmaceutical Ingredients
    • 6.3.2 Inactive Ingredients
  • 6.4 Generic Drugs Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Clinics

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Generic Drugs Sales Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Generic Drugs Sales market is categorized based on

By Product Type

• Generic Prescribed Drugs
• Over-the-Counter Generic Drugs
• Generic Biologics
• Generic Vaccines
• Generic Topical Medications

By Application

• Cardiovascular Diseases
• Central Nervous System Disorders
• Oncology
• Diabetes
• Respiratory Diseases

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Clinics

By Ingredient Type

• Active Pharmaceutical Ingredients
• Inactive Ingredients

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Teva Pharmaceutical Industries Ltd.
• Mylan N.V. (now part of Viatris)
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories
• Amgen Inc.
• Roche Holding AG
• Pfizer Inc.
• Sandoz International GmbH
• Novartis AG
• Hikma Pharmaceuticals Plc
• Apotex Inc.
• Alvogen
• Zydus Cadila
• Lupin Pharmaceuticals
• Glenmark Pharmaceuticals Ltd.